【摘要】 目的 探讨沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤的疗效及对患者血清VEGF水平的影响研究。方法 选取2017年1月—2021年10月吉林省人民医院血液科收治的120例弥漫大B细胞淋巴瘤患者为研究对象，随机分为对照组和观察组，每组60例。对照组采取CHOP方案治疗，观察组采取沙利度胺联合CHOP方案治疗，对比两组患者的治疗效果以及血清VEGF水平变化情况。结果 观察组患者的客观缓解率为93.33%，明显高于对照组的76.67%，差异有统计学意义（χ~2=6.535,P=0.010）。治疗前，两组患者的VEGF水平对比，差异无统计学意义（χ~2=0.146,P=0.883）；治疗后，两组患者的VEGF水平均出现了降低，且观察组患者的VEGF水平更低，差异有统计学意义（χ~2=14.185,P<0.001）。观察组患者的不良反应发生率为30.00%，低于对照组的38.33%，但差异无统计学意义（P>0.05）。结论 沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤可获得更好的治疗有效率，且可有效降低血清VEGF水平，同时也具有更好的安全性。更多还原

【Abstract】 Objective To investigate the efficacy of thalidomide combined with CHOP in the treatment of diffuse large B-cell lymphoma and the effect of serum VEGF level in patients.Methods A total of 120 patients with diffuse large B-cell lymphoma admitted to the Department of Hematology,Jilin Provincial People’s Hospital from January 2017 to October 2021 selected as the study objects and were randomly divided into control group and observation group,with60 cases in each group.The control group was treated CHOP regimen,and the observation group was thalidomide combined with CHOP plan.The treatment effect and serum VEGF level changes of the two groups were compared.Results The objective remission rate of the observation group was 93.33%,which was significantly higher than 76.67%of the control group,and the difference was statistically significant (χ~2=6.535,P=0.010).There was no statistically significant difference in VEGF levels between the two groups before treatment (χ~2=0.146,P=0.883);after treatment,the VEGF levels of the two groups decreased,and the VEGF level of the observation group was lower,the difference was statistically significant (χ~2=14.185,P<0.001).The observation group had lower incidence of adverse reactions as30.00%than 38.33%in the control group,but the difference was not statistically significant (P>0.05).Conclusion Thalidomide combined with CHOP in the treatment of diffuse large B-cell lymphoma can achieve better treatment efficiency,effectively reduce serum VEGF level,and has better safety.更多还原